XWAR
DMG
Market cap76mUSD
Apr 02, Last price
3.42PLN
Name
Global Cosmed SA
Chart & performance
P/E
13.44
P/S
0.67
EPS
0.25
Div yield, %
—
Shrs. gr., 5y
0.27%
Rev. gr., 5y
5.36%
Revenues
444m
+12.08%
Net income
22m
P
CFO
31m
+438.83%
Dividend
Jun 28, 20220.03 PLN/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Global Cosmed S.A. is a Polish company specializing in the manufacturing, sale, and international export of a diverse range of cosmetic and household chemical products. Its extensive product lineup includes various bath and shower essentials such as bubble baths, shower gels, bath foams, and oils, alongside hair and body washes, and shampoos. For laundry care, they provide stain removers, additives, washing balms, concentrated fabric softeners, and both powder and liquid detergents. The company also offers general personal care items, including specialized baby products like nappy, wind, and weather protection creams, as well as children's body wash cosmetics. Global Cosmed S.A. markets its offerings through prominent brands such as Apart Natural, Calinda, Bobini Baby, Bobini, Sofin, Bobini vegan, Kret, Triks, and Domal. Founded in 1990, the company is headquartered in Radom, Poland.
Key people
Andreas Mielimonka
Chairman of the Management Board · since 2016
Jolanta Eugenia Kubicka
Vice Chairman of the Supervisory Board · since 2016
Magdalena Anita Mielimonka
Vice Chairman of the Management Board · since 2016
Pawel Konrad Szymonik
Finance Director, Member of the Management Board · since 2016
Aleksandra Gawronska
Chairman of the Supervisory Board · since 2017
Marian Wlodzimierz Sulek
Independent Member of the Supervisory Board
Tomasz Wasilewski
Independent Member of the Supervisory Board
Milosz Mariusz Wojszko
Member of the Supervisory Board · since 2018
Headquarters & legal address
RADOM WIELKOPOLSKA 3
RADOM, 14 26-600
PL
RADOM, 14 26-600
PL
Previous name
Global Cosmed Spółka Akcyjna
Valuation
Title PLN in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||
Revenues | ||||||||
Cost of revenue | ||||||||
Unusual Expense (Income) | ||||||||
NOPBT | ||||||||
NOPBT Margin | ||||||||
Operating Taxes | ||||||||
Tax Rate | ||||||||
NOPAT | ||||||||
Net income | ||||||||
Dividends | ||||||||
Dividend yield | ||||||||
Proceeds from repurchase of equity | ||||||||
BB yield | ||||||||
| Debt | ||||||||
Debt current | ||||||||
Long-term debt | ||||||||
Deferred revenue | ||||||||
Other long-term liabilities | ||||||||
Net debt | ||||||||
| Cash flow | ||||||||
Cash from operating activities | ||||||||
CAPEX | ||||||||
Cash from investing activities | ||||||||
Cash from financing activities | ||||||||
FCF | ||||||||
| Balance | ||||||||
Cash | ||||||||
Long term investments | ||||||||
Excess cash | ||||||||
Stockholders' equity | ||||||||
Invested Capital | ||||||||
ROIC | ||||||||
ROCE | ||||||||
| EV | ||||||||
Common stock shares outstanding | ||||||||
Price | ||||||||
Market cap | ||||||||
EV | ||||||||
EBITDA | ||||||||
EV/EBITDA | ||||||||
Interest | ||||||||
Interest/NOPBT | ||||||||